Peroxisome proliferator-activated receptor-gamma gene polymorphism and risk of cardiovascular disease in patients with diabetic nephropathy

American Journal of Nephrology

Volumn 28, Issue 5, 2008, Pages 715-722

  Szeto, Cheuk Chun ^a   Chow, Kai Ming ^a   Poon, Peter Yam Kau ^a   Kwan, Bonnie Ching Ha ^a   Li, Philip Kam Tao ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cardiovascular disease; Genetics; Renal failure

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AGED; ARTICLE; C161T GENE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MORTALITY; P12A GENE; PERITONEAL DIALYSIS; PEROXISOME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR GENE; VASCULAR DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; DIABETIC NEPHROPATHIES; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PPAR GAMMA; PROSPECTIVE STUDIES;

EID: 51149110542     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000127452     Document Type: Article

References (33)

1. Ho YW, Chau KF, Leung CB, Choy BY, Tsang WK, Wong PN, Cheng YL, Lai WM, Yong DS, Kwan TH, Lui SF: Hong Kong Registry Report 2004. Hong Kong J Nephrol 2005;7:38-46.
2. Constatini E: United States Renal Data System 2006 Annual Data Report. Am J Kidney Dis 2007;49(suppl 1):s1-s296.
3. Weiner DE, Tabatabai S, Tighiouart H, Elsayed E, Bansal N, Griffith J, Salem DN, Levey AS, Sarnak MJ: Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis 2006;48:392-401.
4. Levin A: Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial 2003;16:101-105.
5. Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 2004;351:1106-1118.
6. Spiegelman BM: PPAR (adipogenic regulator and thiazolidinedione receptor). Diabetes 1998;47:507-514.
7. Cranberry MC, Schneider EF, Fonseca VA: The role of troglitazone in treating the insulin resistance syndrome. Pharmacotherapy 1998;18:973-987.
8. Maggs DG, Buchanan TA, Burant CF, Cline G, Gumbiner B, Hsueh WA: Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus: a randomized, doubled-blind, placebo-controlled trial. Ann Intern Med 1998;128:176-185.
9. Schwartz S, Raskin P, Fonseca V, Graveline JF: Effect of troglitazone in insulin treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. N Engl J Med 1998;338:861-866.
10. Paracchini V, Pedotti P, Taioli E: Genetics of leptin and obesity: a HuGE review. Am J Epidemiol 2005;162:101-114.
11. Ristow M, Muller-Wieland D, Pfeiffer A, Krone W, Kahn CR: Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 1998;339:953-959.
12. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S: Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999;402:880-883.
13. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, Burns DK, Roth J, Shuldiner AR: Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 1997;241:270-274.
14. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Lebel P, Dallongeville J, Deeb S, Auwerx J, Amouyel P: A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. Hum Mol Genet 1998;7:435-440.
15. Orio F Jr, Matarese G, Di Biase S, Palomba S, Labella D, Sanna V, Savastano S, Zullo F, Colao A, Lombardi G: Exon 6 and 2 peroxisome proliferator-activated receptor-gamma polymorphisms in polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:5887-5892.
16. Wang XL, Oosterhof J, Duarte N: Peroxisome proliferator-activated receptor gamma C161 → T polymorphism and coronary artery disease. Cardiovasc Res 1999;44:588-594.
17. Ogawa S, Urano T, Hosoi T, Miyao M, Hoshino S, Fujita M, Shiraki M, Orimo H, Ouchi Y, Inoue S: Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARgamma expression in osteoblasts. Biochem Biophys Res Commun 1999;260:122-126.
18. Chao TH, Li YH, Chen JH, Wu HL, Shi GY, Liu PY, Tsai WC, Guo HR: The 161TT genotype in the exon 6 of the peroxisome-proliferator-activated receptor gamma gene is associated with premature acute myocardial infarction and increased lipid peroxidation in habitual heavy smokers. Clin Sci (Lond) 2004;107:461-466.
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373-383.
20. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Xu JS, Huang SM, Wang LN, Huang W, Wang M, Xu GB, Wang HY: Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006;17:2937-2944.
21. Szeto CC, Wong TY, Chow KM, Leung CB, Li PK: Are peritoneal dialysis patients with and without residual renal function equivalent for survival study? Insight from a retrospective review of the cause of death. Nephrol Dial Transplant 2003;18:977-982.
22. Goraya TY, Jacobsen SJ, Belau PG, Weston SA, Kottke TE, Roger VL: Validation of death certificate diagnosis of out-of-hospital coronary heart disease deaths in Olmsted County, Minnesota. Mayo Clin Proc 2000;75:681-687.
23. Cox D: Regression models and life-tables. J R Stat Soc 1972;34:187-201.
24. Kao WH, Coresh J, Shuldiner AR, Boerwinkle E, Bray MS, Brancati FL: Pro12Ala of the peroxisome proliferator-activated receptor-gamma2 gene is associated with lower serum insulin levels in nonobese African-Americans: the Atherosclerosis Risk in Communities Study. Diabetes 2003;52:1568-1572.
25. Radha V, Vimaleswaran KS, Babu HN, Abate N, Chandalia M, Satija P, Grundy SM, Ghosh S, Majumder PP, Deepa R, Rao SM, Mohan V: Role of genetic polymorphism peroxisome proliferator-activated receptor-gamma2 Pro12Ala on ethnic susceptibility to diabetes in South-Asian and Caucasian subjects: evidence for heterogeneity. Diabetes Care 2006;29:1046-1051.
26. Ek J, Andersen G, Urhammer SA, Hansen L, Carstensen B, Borch-Johnsen K, Drivsholm T, Berglund L, Hansen T, Lithell H, Pedersen O: Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia 2001;44:1170-1176.
27. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471.
28. Rosen CJ: The rosiglitazone story: lessons from an FDA Advisory Committee meeting. N Engl J Med 2007;357:844-846.
29. Muller YL, Bogardus C, Beamer BA, Shuldiner AR, Baier LJ: A functional variant in the peroxisome proliferator-activated receptor gamma2 promoter is associated with predictors of obesity and type 2 diabetes in Pima Indians. Diabetes 2003;52:1864-1871.
30. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD: Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003;63:793-808.
31. Kalantar-Zadeh K, Kilpatrick RD, Kuwae N, Wu DY: Reverse epidemiology: a spurious hypothesis or a hardcore reality? Blood Purif 2005;23:57-63.
32. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC: Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 2004;43:1439-1444.
33. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ: Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004;291:451-459.